Open Access Unrestricted online access star

Cardiovascular diseases (CVD) are the leading causes of mortality in patients with diabetes, and many factors, including hypertension, contribute to this high prevalence of CVD. The current evidence regarding these diseases is quickly expanding, especially in the vascular mechanisms that predispose someone to both conditions. Furthermore, several novel therapies, such as sodium glucose co-transporter 2 inhibitors, have recently beenshown to have benefits against CVD in patients with type 2 diabetes. With these reasons in mind, the need for updated clinical studies in these fields to optimize the outcomes of patients with diabetes, hypertension, and cardiovascular diseases arises. Finally, as we know that diabetes, hypertension, and especially CVD are associated with severity and mortality in patients with COVID-19 infection, we also invited colleagues around the world to report their clinical insights with these comorbidities and COVID-19 in order to provide support in this fundamental area during the pandemic.

Creative Commons Licence cc by-nc-nd cc https://creativecommons.org/licenses/by-nc-nd/4.0/

eng

Freely available e-book